MENU

Click here to

×

Are you sure ?

Yes, do it No, cancel

Summary and Insights Into the TG-43U1S2 Report On Brachytherapy Dosimetry

W Butler1*, F Ballester2*, M Rivard3*, (1) Wheeling Hospital, Wheeling, WV, (2) University of Valencia, Burjassot,(3) Rhode Island Hospital/Warren Alpert Medical, Providence, RI




Presentations

(Monday, 7/30/2018) 7:30 AM - 8:25 AM

Room: Davidson Ballroom B

Since publication of the 2004 update to AAPM Task Group No. 43 Report (TG-43U1) and its 2007 supplement (TG-43U1S1), 11 new low-energy photon-emitting brachytherapy sources have become available. Many of these sources have satisfied the AAPM prerequisites for routine clinical purposes and are posted on the Brachytherapy Source Registry managed jointly by the AAPM and the Imaging and Radiation Oncology Core Houston Quality Assurance Center (IROC Houston). Given increasingly closer interactions among physicists in North America and Europe, the AAPM and the Groupe Européen de Curiethérapie-European Society for Radiotherapy & Oncology (GEC-ESTRO) have prepared another supplement/report containing recommended brachytherapy dosimetry parameters. The TG-43U1S2 report was published in Medical Physics (September 2017). The proposed educational session will summarize this TG-43U1S2 report, present consensus datasets approved by the AAPM and GEC-ESTRO, outline methods used to formulate these consensus datasets, and review recommendations to vendors of brachytherapy sources and treatment planning systems. Also covered will be reference data for brachytherapy dosimetry investigations such as radionuclide source spectra and half-lives, reference dose scoring media, and TLD methodological corrections. Finally, observations on the behavior of consensus dosimetry parameters as a function of radionuclide, and the influence of consensus dataset grid size will be discussed.

Learning Objectives:
1. understand the method for deriving a consensus dataset with 11 practical
examples
2. become familiar with recommendations to vendors of brachytherapy sources and
treatment planning systems
3. identify reference data for brachytherapy dosimetry investigations such as
radionuclide source spectra and half-lives, reference dose scoring media, and TLD
methodological corrections

Funding Support, Disclosures, and Conflict of Interest: Research support for Rivard provided by GE Healthcare, CivaTech Oncology, and IsoRay Medical.

Handouts

Keywords

Not Applicable / None Entered.

Taxonomy

Not Applicable / None Entered.

Contact Email